WO2004064710A3 - Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas - Google Patents

Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas Download PDF

Info

Publication number
WO2004064710A3
WO2004064710A3 PCT/DE2004/000092 DE2004000092W WO2004064710A3 WO 2004064710 A3 WO2004064710 A3 WO 2004064710A3 DE 2004000092 W DE2004000092 W DE 2004000092W WO 2004064710 A3 WO2004064710 A3 WO 2004064710A3
Authority
WO
WIPO (PCT)
Prior art keywords
gstm
diagnosis
applications
treatment
substances binding
Prior art date
Application number
PCT/DE2004/000092
Other languages
German (de)
French (fr)
Other versions
WO2004064710A2 (en
Inventor
Bernd Hinzmann
Edgar Dahl
Thomas Specht
Christian Pilarsky
Alexander Herr
Original Assignee
Bernd Hinzmann
Edgar Dahl
Thomas Specht
Christian Pilarsky
Alexander Herr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernd Hinzmann, Edgar Dahl, Thomas Specht, Christian Pilarsky, Alexander Herr filed Critical Bernd Hinzmann
Publication of WO2004064710A2 publication Critical patent/WO2004064710A2/en
Publication of WO2004064710A3 publication Critical patent/WO2004064710A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The invention relates to applications of GSTM for the diagnosis and treatment of urogenital tumours, in particular, cystic carcinomas and for screening for substances for such purposes.
PCT/DE2004/000092 2003-01-16 2004-01-16 Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas WO2004064710A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10301592.2 2003-01-16
DE2003101592 DE10301592A1 (en) 2003-01-16 2003-01-16 Use of substances binding to GSTM for the diagnosis and treatment of bladder cancer

Publications (2)

Publication Number Publication Date
WO2004064710A2 WO2004064710A2 (en) 2004-08-05
WO2004064710A3 true WO2004064710A3 (en) 2005-05-12

Family

ID=32667635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/000092 WO2004064710A2 (en) 2003-01-16 2004-01-16 Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas

Country Status (2)

Country Link
DE (1) DE10301592A1 (en)
WO (1) WO2004064710A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033424A1 (en) * 2005-09-23 2007-03-29 Australian National University Compositions and methods for transfecting cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKTAS DILEK: "Glutathione S-Transferase M1 (GSTM1) gene polymorphism in bladder cancer patients: Is a marker for invasive bladder cancer?", EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 7, no. SUPPL. 1, July 1999 (1999-07-01), & 31ST ANNUAL MEETING OF THE EUROPEAN SOCIETY OF HUMAN GENETICS; GENEVA, SWITZERLAND; MAY 29-JUNE 1, 1999, pages 83, XP009037553, ISSN: 1018-4813 *
ENGEL LAWRENCE S ET AL: "Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A HuGE review", AMERICAN JOURNAL OF EPIDEMIOLOGY, vol. 156, no. 2, 15 July 2002 (2002-07-15), pages 95 - 109, XP009037557, ISSN: 0002-9262 *
JOHNS L E ET AL: "GLUTATHIONE S-TRANSFERASE MU1 (GSTM1) STATUS AND BLADDER CANCER RISK: A META-ANALYSIS", MUTAGENESIS, IRL PRESS, OXFORD, GB, vol. 15, no. 5, September 2000 (2000-09-01), pages 399 - 404, XP009037550, ISSN: 0267-8357 *

Also Published As

Publication number Publication date
WO2004064710A2 (en) 2004-08-05
DE10301592A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2005060377A3 (en) Modulation of immunostimulatory properties by small oligonucleotide-based compounds
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2007051164A8 (en) Toll like receptor 3 modulators, methods and uses
EP2311877A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
IL229509A0 (en) Compositions containing chemically modified small molecules and methods utilizing the same
AU2006239917A8 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
EP1421203A4 (en) Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
WO2006015263A3 (en) Lonidamine analogs
EP1940456A4 (en) Wwox gene, vectors containing the same, and uses in treatment of cancer
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005054871A3 (en) Analysis of mass spectral data in the quiet zones
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
MX2007007355A (en) 5-(2,2-dimethyl-cycloprodyl)-3-methyl-pen-2-enenitrile as fragrance and flavour.
WO2004067564A3 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2004064710A3 (en) Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 25-11-2005)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69 (1) EPC (EPO FORM 1205A DATED 25-11-2006

122 Ep: pct application non-entry in european phase